

Antibody Discovery Services Market by Type (Target Identification, Antibody Engineering (Technology (Hybridoma, Phage Display, Single Cell)), Immunization), Host (Mouse, Rat, Rabbit, Chicken, Camelids), Molecule (Monoclonal) - Global Forecast to 2030

<https://marketpublishers.com/r/A4CA08D15880EN.html>

Date: September 2025

Pages: 380

Price: US\$ 4,950.00 (Single User License)

ID: A4CA08D15880EN

Abstracts

The antibody discovery services market is expected to reach 3.54 billion in 2030 from USD 1.90 billion in 2024, at a CAGR of 13.3% during the forecast period. Factors propelling the antibody discovery services market include the development of advanced formats such as bispecific antibodies (bsAbs) and ADCs, alongside rising venture funding and strategic partnerships. Moreover, the integration of AI and adoption of end-to-end service models are streamlining workflows, enhancing efficiency, and accelerating innovation in the field.

The mice & rats segment accounted for the largest share of the antibody discovery immunization & host management services market in 2024.

The market is segmented into mice & rats, rabbits, chickens, camelids, and other hosts. In 2024, the mouse & rat segment accounted for the largest share of the antibody discovery immunization & host management services market. These species remain the preferred choice due to their genetic similarity to humans, cost-effectiveness, and highly optimized breeding and experimental protocols. Their widespread use reflects well-established immunization workflows and robust host management infrastructure in preclinical antibody discovery efforts. Furthermore, the prevalence of mouse and rat models supports scalable, reproducible immunization services, facilitating rapid antibody generation through tried-and-tested immunological methods. This

segmentation also enables service providers to tailor immunization strategies and host handling practices to well-characterized animal systems, enhancing predictability and efficiency. Collectively, these advantages cement the mouse & rat host segment as the dominant segment in immunization and host management services within the antibody discovery services market.

In 2024, by end user, the pharmaceutical & biotechnology companies segment accounted for the largest share of the market.

The antibody discovery services market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and other end users. In 2024, the pharmaceutical & biotechnology companies segment accounted for the largest share of the antibody discovery services market, driven by the scale of research and development activities directed toward therapeutic antibody programs. These companies manage extensive pipelines that require continuous discovery of new antibody candidates across oncology, immunology, infectious diseases, and other therapeutic areas. They invest heavily in advanced technologies such as phage display, hybridoma, and AI-based screening platforms provided by specialized service providers to support this. The high demand for outsourcing also reflects the need to streamline timelines, reduce internal costs, and access capabilities unavailable in-house. In addition, pharmaceutical and biotechnology firms pursue partnerships and collaborations that expand access to discovery platforms, enabling them to move efficiently from target identification to preclinical evaluation. The combination of broad therapeutic focus, large-scale investments, and reliance on external expertise established these companies as the leading contributors to market demand in 2024.

In 2024, North America accounted for the largest share of the antibody discovery services market.

North America accounted for the largest share of the antibody discovery services market in 2024. The region accounted for this position due to its concentration of pharmaceutical and biotechnology companies, research institutes, and contract service providers engaged in antibody development. Extensive funding for biomedical research from government agencies and private investors created a steady demand for discovery services. North America also benefits from a mature regulatory framework that supports the advancement of antibody-based therapeutics, enabling efficient progression from discovery to clinical evaluation. The presence of advanced research infrastructure, a skilled workforce, and established technology platforms further strengthened the region's capacity to utilize and expand antibody discovery services. In addition, high

clinical trial activity and strong collaborations between industry and academia contributed to sustained demand. Collectively, these factors positioned North America as the leading region in the global antibody discovery services market in 2024.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%

By Designation: C-level Executives - 55%, Directors- 20%, and Others- 25%

By Region: North America -45%, Europe - 20%, Asia Pacific -20%, Latin America -10%, the Middle East- 3%, and Africa-2%

Charles River Laboratories (US), Thermo Fisher Scientific Inc. (US), WuXi Biologics (China), Aurigene Pharmaceutical Services Ltd. (India), EVOTEC (Germany), Sino Biological, Inc. (China), Shanghai ChemPartner (China), Biocytogen (China), Samsung Biologics (South Korea), Fusion Antibodies (UK), Twist Bioscience (US), Curia Global, Inc. (US), Danaher Corporation (US), Eurofins Scientific (Luxembourg), GenScript (US), Creative Biolabs (US), Viva Biotech (China), Harbour BioMed (China), ImmunoPrecise Antibodies Ltd. (Canada), Aragen Life Sciences Ltd. (India) are some of the key companies offering Antibody Discovery Services products.

Research Coverage

This research report categorizes the Antibody Discovery Services market by Type [Target Identification & Validation, Antibody Engineering & Optimization (Phage/Yeast Display Technology, Hybridoma Technology, Single-Cell Technologies, Other Technologies), Antigen Design & Production, Immunization & Host Management, Other Services], Immunization & Host Management By Host (Mice & Rats, Rabbits, Chickens, Camelids, Other Hosts), Molecule (Monoclonal Antibodies, Polyclonal Antibodies, Other Molecules), End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Other End Users), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the Antibody Discovery Services market. A detailed analysis of the key industry players has provided insights into their business overview, service portfolio, key strategies such as collaborations, partnerships, expansions, agreements, acquisitions, and recent developments associated with the antibody

discovery services market. This report covers a competitive analysis of top players and upcoming startups in the Antibody Discovery Services market ecosystem.

The scope of the report covers detailed information regarding the primary factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the Antibody Discovery Services market. A thorough analysis of the key industry players has been conducted to provide insights into their business overview, solutions, and services; key strategies; new product & service launches, acquisitions, and recent developments associated with the Antibody Discovery Services market. This report covers the competitive analysis of upcoming startups in the Antibody Discovery Services market ecosystem.

Key Benefits of Buying the Report

This report provides a detailed picture of the antibody discovery services market. It aims to estimate the size and future growth potential of the market across different segments such as the type, host, molecule, end user, and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles, recent developments, and key market strategies.

The report provides insights into the following pointers:

Analysis of key drivers (Development of new antibody formats, growing number of ADCs in clinical trials, rising funds for venture and partnership for biologics), restraints (High cost & complexity of biologics discovery, competition from alternative modalities, patent cliffs and rise of biosimilars), opportunities (end-to-end discovery-to-IND service bundles, integration of AI and automation in discovery workflow), Challenges (reagent & raw material supply chain bottlenecks, fragmented data and workflow infrastructure)

Service Development/Innovation: Detailed insights on newly launched Services, and technological assessment of the antibody discovery services market.

Market Development: Comprehensive information about lucrative markets – the report analyses the antibody discovery services market across varied regions.

Market Diversification: Exhaustive information about new, untapped geographies, recent developments, and investments in the antibody discovery services market

Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Charles River Laboratories (US), Thermo Fisher Scientific Inc. (US), WuXi Biologics (China), Aurigene Pharmaceutical Services Ltd. (India), EVOTEC (Germany), among others in the antibody discovery services market.

Contents

1 INTRODUCTION

- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
 - 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
 - 1.3.2 INCLUSIONS & EXCLUSIONS
- 1.4 YEARS CONSIDERED
 - 1.4.1 CURRENCY CONSIDERED
- 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

- 2.1 RESEARCH DATA
 - 2.1.1 SECONDARY DATA
 - 2.1.1.1 Key secondary data sources
 - 2.1.1.2 Key objectives of secondary research
 - 2.1.2 PRIMARY DATA
 - 2.1.2.1 Breakdown of primaries
 - 2.1.2.2 Key objectives of primary research
- 2.2 MARKET ESTIMATION METHODOLOGY
 - 2.2.1 MARKET ESTIMATION
 - 2.2.1.1 Company revenue analysis (bottom-up approach)
 - 2.2.1.2 MnM repository analysis & primary interviews
 - 2.2.1.3 Insights from primary experts
 - 2.2.1.4 Segmental market size estimation by top-down approach
- 2.3 MARKET GROWTH RATE PROJECTIONS
- 2.4 DATA TRIANGULATION
- 2.5 STUDY ASSUMPTIONS
- 2.6 RESEARCH LIMITATIONS
- 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

- 3.1 KEY INSIGHTS & MARKET HIGHLIGHTS
- 3.2 STRATEGIC IMPERATIVES FOR KEY STAKEHOLDERS
- 3.3 DISRUPTIVE TRENDS SHAPING ANTIBODY DISCOVERY SERVICES MARKET

3.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS

3.5 GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 60 4 PREMIUM INSIGHTS

4.1 ANTIBODY DISCOVERY SERVICES MARKET OVERVIEW

4.2 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE AND COUNTRY (2024)

4.3 ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2025 VS. 2030

4.4 ANTIBODY DISCOVERY SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

4.5 ANTIBODY DISCOVERY SERVICES MARKET SHARE, BY TYPE

4.6 UNMET NEEDS & WHITE SPACES

4.7 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES

4.8 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS

4.9 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

4.10 VC/PRIVATE EQUITY INVESTMENT TRENDS

4.11 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES

4.11.1 SUSTAINABILITY IMPACT

4.11.2 REGULATORY POLICIES & ACCESS INITIATIVES

4.12 IP/PATENT LANDSCAPE IN ANTIBODY DISCOVERY SERVICES MARKET

5 MARKET OVERVIEW

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

5.2.1 DRIVERS

5.2.1.1 Development of bispecific antibodies and antibody fragments

5.2.1.2 Rising number of antibody-drug conjugates in clinical trials

5.2.1.3 Increasing venture and partnership funding for biologics

5.2.2 RESTRAINTS

5.2.2.1 High costs and complexity of biologics discovery

5.2.2.2 Competition from alternative modalities

5.2.2.3 Patent cliffs for blockbuster monoclonal antibodies and rise of biosimilars

5.2.3 OPPORTUNITIES

5.2.3.1 End-to-end discovery-to-IND service bundles/one-stop shop models in antibody discovery

5.2.3.2 Integration of AI and automation in discovery workflow

5.2.4 CHALLENGES

5.2.4.1 Reagents and raw material supply chain bottlenecks

5.2.4.2 Fragmented data and disjointed workflow infrastructure 76 6 INDUSTRY

TRENDS

6.1 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS

6.2 VALUE CHAIN ANALYSIS

6.3 ECOSYSTEM ANALYSIS

6.3.1 RAW MATERIAL SUPPLIERS

6.3.2 ANTIBODY DISCOVERY SERVICE PROVIDERS

6.3.3 END USERS

6.3.4 REGULATORY BODIES

6.4 INVESTMENT & FUNDING SCENARIO

6.4.1 MAJOR INVESTMENTS AND FUNDING

6.5 TECHNOLOGY ANALYSIS

6.5.1 KEY TECHNOLOGIES

6.5.1.1 Phage display platforms

6.5.1.2 Hybridoma technology

6.5.1.3 Single B-cell screening

6.5.2 COMPLEMENTARY TECHNOLOGIES

6.5.2.1 AI/ML-based protein structure prediction

6.5.2.2 Surface plasmon resonance (SPR)/Bio-layer interferometry (BLI)

6.5.2.3 Cryo-electron microscopy (CRYO-EM)

6.5.3 ADJACENT TECHNOLOGIES

6.5.3.1 CRISPR-based functional genomics

6.5.3.2 CHO cell line development

6.5.3.3 In-vivo modelling

6.6 PATENT ANALYSIS

6.6.1 METHODOLOGY

6.6.2 NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014-2024

6.6.3 LIST OF KEY PATENTS

6.7 KEY CONFERENCES & EVENTS, 2025-2026

6.8 CASE STUDY ANALYSIS

6.8.1 BISPECIFIC ANTIBODY MANUFACTURABILITY ASSESSMENT AND OPTIMIZATION

6.8.2 ACCELERATING ANTIBODY DISCOVERY FOR PANDEMIC PREPAREDNESS

6.8.3 USE OF REPAB POLYCLONAL ANTIBODY SEQUENCING PLATFORM TO IDENTIFY PROTECTIVE ANTIBODIES FROM HUMAN HOSTS IMMUNE TO MALARIA

6.9 REGULATORY ANALYSIS

6.9.1 REGULATORY LANDSCAPE

6.9.1.1 North America

6.9.1.2 Europe

6.9.1.3 Asia Pacific

6.9.1.4 Rest of the World

6.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

6.10 PORTER'S FIVE FORCES ANALYSIS

6.10.1 BARGAINING POWER OF SUPPLIERS

6.10.2 BARGAINING POWER OF BUYERS

6.10.3 THREAT OF NEW ENTRANTS

6.10.4 THREAT OF SUBSTITUTES

6.10.5 INTENSITY OF COMPETITIVE RIVALRY

6.11 KEY STAKEHOLDERS & BUYING CRITERIA

6.11.1 KEY STAKEHOLDERS IN BUYING PROCESS

6.11.2 KEY BUYING CRITERIA

6.12 IMPACT OF AI/GEN AI ON ANTIBODY DISCOVERY SERVICES MARKET

6.12.1 INTRODUCTION

6.12.2 MARKET POTENTIAL OF AI

7 ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE

7.1 INTRODUCTION

7.2 TARGET IDENTIFICATION & VALIDATION

7.2.1 INTEGRATION OF OMICS-DRIVEN INSIGHTS WITH HIGH-THROUGHPUT FUNCTIONAL VALIDATION TO PROPEL MARKET GROWTH

7.3 ANTIBODY ENGINEERING & OPTIMIZATION

7.3.1 ANTIBODY ENGINEERING & OPTIMIZATION, BY TECHNOLOGY

7.3.1.1 Phage display technology

7.3.1.1.1 Adoption of AI-enhanced phage display to augment segment growth

7.3.1.2 Hybridoma technology

7.3.1.2.1 Advancements in automation and single-cell integration to support segment growth

7.3.1.3 Single-cell technologies

7.3.1.3.1 Use of high-throughput, single-cell platforms to boost segment growth

7.3.1.4 Other antibody engineering & optimization technologies

7.4 ANTIGEN DESIGN & PRODUCTION

7.4.1 HIGH-QUALITY ANTIGEN DESIGN AND PRODUCTION TO SPUR SEGMENT GROWTH

7.5 IMMUNIZATION & HOST MANAGEMENT

7.5.1 RISING ADOPTION OF ADVANCED TRANSGENIC AND HUMANIZED MODELS TO PROPEL SEGMENT GROWTH

7.6 OTHER ANTIBODY DISCOVERY SERVICES

8 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST

8.1 INTRODUCTION

8.2 MOUSE & RAT

8.2.1 GROWING PRECLINICAL RESEARCH DEMAND TO DRIVE GROWTH 137 8.3 RABBIT

8.3.1 INCREASED RESEARCH AND DIAGNOSTIC APPLICATIONS TO FAVOR MARKET GROWTH

8.4 CHICKEN

8.4.1 INCREASING FOCUS OF THERAPEUTIC AND DIAGNOSTIC APPLICATIONS TO DRIVE MARKET

8.5 CAMELIDS

8.5.1 RISING ADOPTION OF NANOBODIES IN THERAPEUTICS AND DIAGNOSTICS TO BOOST MARKET GROWTH

8.6 OTHER HOSTS

9 ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE

9.1 INTRODUCTION

9.2 MONOCLONAL ANTIBODIES

9.2.1 GROWING ADOPTION IN TISSUE TYPING FOR ORGAN & BLOOD TRANSPLANTS AND PERSONALIZED MEDICINES TO DRIVE MARKET

9.3 POLYCLONAL ANTIBODIES

9.3.1 DIVERSE EPITOPE RECOGNITION ABILITY OF POLYCLONAL ANTIBODIES TO SUPPORT SEGMENT GROWTH

9.4 OTHER MOLECULES

10 ANTIBODY DISCOVERY SERVICES MARKET, BY END USER

10.1 INTRODUCTION

10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

10.2.1 STRATEGIC COLLABORATIONS AND AI INTEGRATION TO BOLSTER GROWTH

10.3 ACADEMIC & RESEARCH INSTITUTES

10.3.1 INCREASING COLLABORATIVE RESEARCH AND RISING GRANT FUNDING TO AUGMENT MARKET GROWTH

10.4 OTHER END USERS

11 ANTIBODY DISCOVERY SERVICES MARKET, BY REGION

11.1 INTRODUCTION

11.2 NORTH AMERICA

11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA

11.2.2 US

11.2.2.1 US to dominate antibody discovery services market during forecast period

11.2.3 CANADA

11.2.3.1 Innovative biotech community and strategic platform investments to propel market growth

11.3 EUROPE

11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE

11.3.2 GERMANY

11.3.2.1 Transformative cross-border acquisitions and platform-driven antibody innovation to expedite market growth

11.3.3 UK

11.3.3.1 Ramped ADC innovation and surging biotech investment to propel market growth

11.3.4 FRANCE

11.3.4.1 Strategic biomanufacturing investments and AI-enabled innovation to support market expansion

11.3.5 ITALY

11.3.5.1 Advanced R&D infrastructure and biotech innovation to aid market growth

11.3.6 SPAIN

11.3.6.1 High biotech investment and innovation in advanced antibody modalities to drive market

11.3.7 REST OF EUROPE

11.4 ASIA PACIFIC

11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC

11.4.2 CHINA

11.4.2.1 Scalable integrated platforms, strategic global certification, and domestic innovation acceleration to augment market growth

11.4.3 JAPAN

11.4.3.1 Enhanced translational platforms and strategic cross-border R&D partnerships to expedite market growth

11.4.4 INDIA

11.4.4.1 Advanced biomanufacturing platforms and innovation-led public-private partnerships to strengthen Indian market

11.4.5 SOUTH KOREA

11.4.5.1 AI platform investments and CDMO-led modality innovation to accelerate market growth

11.4.6 AUSTRALIA

11.4.6.1 High-throughput single-cell platforms and increased academic-industry collaborations to spur market growth

11.4.7 REST OF ASIA PACIFIC

11.5 LATIN AMERICA

11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA

11.5.2 BRAZIL

11.5.2.1 Local biologics infrastructure expansion and collaborative innovation ecosystems to favor market growth

11.5.3 MEXICO

11.5.3.1 Focus on local emerging startups and industry-academic collaborations to aid antibody discovery services

11.5.4 REST OF LATIN AMERICA

11.6 MIDDLE EAST

11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST

11.6.2 GCC COUNTRIES

11.6.2.1 UAE

11.6.2.1.1 High biomanufacturing investments and focus on global pharmaceutical partnerships to fuel market growth

11.6.2.2 Kingdom of Saudi Arabia

11.6.2.2.1 Advanced biologics infrastructure and strategic life science innovation hubs to bolster market growth

11.6.2.3 Rest of GCC Countries

11.6.3 REST OF MIDDLE EAST

11.7 AFRICA

11.7.1 ADVANCED REGIONAL MANUFACTURING CAPABILITIES AND BIOTECH INNOVATION ECOSYSTEMS TO DRIVE MARKET

11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

12 COMPETITIVE LANDSCAPE

12.1 INTRODUCTION

12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN

12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN ANTIBODY DISCOVERY SERVICES MARKET

12.3 REVENUE ANALYSIS, 2020–2024

12.4 MARKET SHARE ANALYSIS, 2024

12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024

12.5.1 STARS

12.5.2 EMERGING LEADERS

12.5.3 PERVASIVE PLAYERS

12.5.4 PARTICIPANTS

12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024

12.5.5.1 Company footprint

12.5.5.2 Region footprint

12.5.5.3 Type footprint

12.5.5.4 Host footprint

12.5.5.5 Molecule footprint

12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024

12.6.1 PROGRESSIVE COMPANIES

12.6.2 RESPONSIVE COMPANIES

12.6.3 DYNAMIC COMPANIES

12.6.4 STARTING BLOCKS

12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024

12.6.5.1 List of key startups/SMEs

12.6.5.2 Competitive benchmarking of key startups/SMEs

12.7 COMPANY VALUATION & FINANCIAL METRICS

12.7.1 FINANCIAL METRICS

12.7.2 COMPANY VALUATION

12.8 BRAND/SERVICE COMPARISON

12.9 COMPETITIVE SCENARIO

12.9.1 SERVICE LAUNCHES

12.9.2 DEALS

12.9.3 EXPANSIONS

13 COMPANY PROFILES

13.1 KEY PLAYERS

13.1.1 WUXI BIOLOGICS

13.1.1.1 Business overview

13.1.1.2 Services offered

13.1.1.3 Recent developments

13.1.1.3.1 Deals

13.1.1.3.2 Expansions

13.1.1.4 MnM view

- 13.1.1.4.1 Right to win
- 13.1.1.4.2 Strategic choices
- 13.1.1.4.3 Weaknesses & competitive threats
- 13.1.2 THERMO FISHER SCIENTIFIC INC.
 - 13.1.2.1 Business overview
 - 13.1.2.2 Services offered
 - 13.1.2.3 Recent developments
 - 13.1.2.3.1 Deals
 - 13.1.2.3.2 Expansions
 - 13.1.2.4 MnM view
 - 13.1.2.4.1 Right to win
 - 13.1.2.4.2 Strategic choices
 - 13.1.2.4.3 Weaknesses & competitive threats
- 13.1.3 CHARLES RIVER LABORATORIES
 - 13.1.3.1 Business overview
 - 13.1.3.2 Services offered
 - 13.1.3.3 Recent developments
 - 13.1.3.3.1 Deals
 - 13.1.3.4 MnM view
 - 13.1.3.4.1 Right to win
 - 13.1.3.4.2 Strategic choices
 - 13.1.3.4.3 Weaknesses & competitive threats
- 13.1.4 EVOTEC
 - 13.1.4.1 Business overview
 - 13.1.4.2 Services offered
 - 13.1.4.3 Recent developments
 - 13.1.4.3.1 Deals
 - 13.1.4.3.2 Contracts
 - 13.1.4.3.3 Expansions
 - 13.1.4.3.4 Other developments 308
 - 13.1.4.4 MnM view
 - 13.1.4.4.1 Right to win
 - 13.1.4.4.2 Strategic choices
 - 13.1.4.4.3 Weaknesses & competitive threats
- 13.1.5 BIOCYTOGEN
 - 13.1.5.1 Business overview
 - 13.1.5.2 Services offered
 - 13.1.5.3 Recent developments
 - 13.1.5.3.1 Service launches
 - 13.1.5.3.2 Deals

- 13.1.5.3.3 Expansions
- 13.1.5.4 MnM view
 - 13.1.5.4.1 Right to win
 - 13.1.5.4.2 Strategic choices
 - 13.1.5.4.3 Weaknesses & competitive threats
- 13.1.6 EUROFINS SCIENTIFIC
 - 13.1.6.1 Business overview
 - 13.1.6.2 Services offered
 - 13.1.6.3 Recent developments
 - 13.1.6.3.1 Expansions
- 13.1.7 SHANGHAI CHEMPARTNER
 - 13.1.7.1 Business overview
 - 13.1.7.2 Services offered
 - 13.1.7.3 Recent developments
 - 13.1.7.3.1 Deals
- 13.1.8 AURIGENE PHARMACEUTICAL SERVICES LTD. (DR. REDDY'S LABORATORIES)
 - 13.1.8.1 Business overview
 - 13.1.8.2 Services offered
 - 13.1.8.3 Recent developments
 - 13.1.8.3.1 Expansions
- 13.1.9 SINO BIOLOGICAL, INC.
 - 13.1.9.1 Business overview
 - 13.1.9.2 Services offered
 - 13.1.9.3 Recent developments
 - 13.1.9.3.1 Deals
 - 13.1.9.3.2 Expansions
- 13.1.10 SAMSUNG BIOLOGICS
 - 13.1.10.1 Business overview
 - 13.1.10.2 Services offered
 - 13.1.10.3 Recent developments
 - 13.1.10.3.1 Service launches 330
- 13.1.11 GENSCRIPT
 - 13.1.11.1 Business overview
 - 13.1.11.2 Services offered
 - 13.1.11.3 Recent developments
 - 13.1.11.3.1 Service launches
 - 13.1.11.3.2 Deals
- 13.1.12 CURIA GLOBAL, INC.
 - 13.1.12.1 Business overview

- 13.1.12.2 Services offered
- 13.1.12.3 Recent developments
 - 13.1.12.3.1 Deals
 - 13.1.12.3.2 Other developments
- 13.1.13 TWIST BIOSCIENCE
 - 13.1.13.1 Business overview
 - 13.1.13.2 Services offered
 - 13.1.13.3 Recent developments
 - 13.1.13.3.1 Service launches
 - 13.1.13.3.2 Deals
 - 13.1.13.3.3 Expansions
- 13.1.14 HARBOUR BIOMED
 - 13.1.14.1 Business overview
 - 13.1.14.2 Services offered
 - 13.1.14.3 Recent developments
 - 13.1.14.3.1 Deals
 - 13.1.14.3.2 Other developments
- 13.1.15 ARAGEN LIFE SCIENCES LTD.
 - 13.1.15.1 Business overview
 - 13.1.15.2 Services offered
 - 13.1.15.3 Recent developments
 - 13.1.15.3.1 Expansions
- 13.1.16 DANAHER CORPORATION
 - 13.1.16.1 Business overview
 - 13.1.16.2 Services offered
 - 13.1.16.3 Recent developments
 - 13.1.16.3.1 Deals
- 13.1.17 CREATIVE BIOLABS
 - 13.1.17.1 Business overview
 - 13.1.17.2 Services offered
- 13.1.18 VIVA BIOTECH
 - 13.1.18.1 Business overview
 - 13.1.18.2 Services offered
- 355 13.1.19 IMMUNOPRECISE ANTIBODIES LTD.
 - 13.1.19.1 Business overview
 - 13.1.19.2 Services offered
 - 13.1.19.3 Recent developments
 - 13.1.19.3.1 Deals
- 13.1.20 FUSION ANTIBODIES
 - 13.1.20.1 Business overview

13.1.20.2 Services offered

13.2 OTHER PLAYERS

13.2.1 ABZENA

13.2.2 ALLOY THERAPEUTICS, INC.

13.2.3 INTEGRAL MOLECULAR

13.2.4 BODURO

13.2.5 SYN BIO TECHNOLOGIES

13.2.6 ABSOLUTE ANTIBODY

13.2.7 ADIMAB

13.2.8 ISOGENICA

13.2.9 ABLEXIS

13.2.10 FAIRJOURNEY

14 APPENDIX

14.1 DISCUSSION GUIDE

14.2 KNOWLEDGESTORE: MARKET SAND MARKETS' SUBSCRIPTION PORTAL

14.3 CUSTOMIZATION OPTIONS

14.4 RELATED REPORTS

14.5 AUTHOR DETAILS

List Of Tables

LIST OF TABLES

TABLE 1 ANTIBODY DISCOVERY SERVICES MARKET: INCLUSIONS & EXCLUSIONS

TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS IN ANTIBODY DISCOVERY SERVICES MARKET

TABLE 3 ANTIBODY DISCOVERY SERVICES MARKET: RISK ANALYSIS

TABLE 4 KEY IP/PLATFORM ASSETS OF KEY PLAYERS, 2022–2025

TABLE 5 IMPACT ANALYSIS OF ANTIBODY DISCOVERY SERVICES MARKET DYNAMICS

TABLE 6 MAJOR VENTURE AND PARTNERSHIP FUNDING FOR BIOLOGICS, 2025

TABLE 7 ROLE OF RAW MATERIAL SUPPLIERS IN ANTIBODY DISCOVERY SERVICES MARKET ECOSYSTEM

TABLE 8 ROLE OF ANTIBODY DISCOVERY SERVICE PROVIDERS IN ANTIBODY DISCOVERY SERVICES MARKET ECOSYSTEM

TABLE 9 ROLE OF END USERS IN ANTIBODY DISCOVERY SERVICES MARKET ECOSYSTEM

TABLE 10 ROLE OF REGULATORY BODIES IN ANTIBODY DISCOVERY SERVICES MARKET ECOSYSTEM

TABLE 11 NUMBER OF PATENTS FILED (APPLIED/GRANTED) IN ANTIBODY DISCOVERY SERVICES MARKET, 2014–2024

TABLE 12 LIST OF KEY PATENTS IN ANTIBODY DISCOVERY SERVICES MARKET

TABLE 13 LIST OF KEY CONFERENCES & EVENTS IN ANTIBODY DISCOVERY SERVICES MARKET, JANUARY 2025–DECEMBER 2026

TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 17 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 18 ANTIBODY DISCOVERY SERVICES MARKET: PORTER'S FIVE FORCES

TABLE 19 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%), BY TYPE

TABLE 20 KEY BUYING CRITERIA FOR MAJOR END USERS

TABLE 21 KEY PLAYERS IMPLEMENTING AI IN ANTIBODY DISCOVERY SERVICES

TABLE 22 ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 23 TARGET IDENTIFICATION & VALIDATION MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 24 NORTH AMERICA: TARGET IDENTIFICATION & VALIDATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 25 EUROPE: TARGET IDENTIFICATION & VALIDATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 26 ASIA PACIFIC: TARGET IDENTIFICATION & VALIDATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 27 LATIN AMERICA: TARGET IDENTIFICATION & VALIDATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 28 MIDDLE EAST: TARGET IDENTIFICATION & VALIDATION MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 29 GCC COUNTRIES: TARGET IDENTIFICATION & VALIDATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 30 ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 31 NORTH AMERICA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 32 EUROPE: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 33 ASIA PACIFIC: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 34 LATIN AMERICA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 35 MIDDLE EAST: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 36 GCC COUNTRIES: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 37 ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 38 PHAGE DISPLAY TECHNOLOGY MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 39 NORTH AMERICA: PHAGE DISPLAY TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 40 EUROPE: PHAGE DISPLAY TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 41 ASIA PACIFIC: PHAGE DISPLAY TECHNOLOGY MARKET, BY

COUNTRY, 2023–2030 (USD MILLION)

TABLE 42 LATIN AMERICA: PHAGE DISPLAY TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 43 MIDDLE EAST: PHAGE DISPLAY TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 44 GCC COUNTRIES: PHAGE DISPLAY TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 45 HYBRIDOMA TECHNOLOGY MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 46 NORTH AMERICA: HYBRIDOMA TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 47 EUROPE: HYBRIDOMA TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 48 ASIA PACIFIC: HYBRIDOMA TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 49 LATIN AMERICA: HYBRIDOMA TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 50 MIDDLE EAST: HYBRIDOMA TECHNOLOGY MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 51 GCC COUNTRIES: HYBRIDOMA TECHNOLOGY MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 52 SINGLE-CELL TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 53 NORTH AMERICA: SINGLE-CELL TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 54 EUROPE: SINGLE-CELL TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 55 ASIA PACIFIC: SINGLE-CELL TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 56 LATIN AMERICA: SINGLE-CELL TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 57 MIDDLE EAST: SINGLE-CELL TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 58 GCC COUNTRIES: SINGLE-CELL TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 59 OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 60 NORTH AMERICA: OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

- TABLE 61 EUROPE: OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
- TABLE 62 ASIA PACIFIC: OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
- TABLE 63 LATIN AMERICA: OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
- TABLE 64 MIDDLE EAST: OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY REGION, 2023–2030 (USD MILLION)
- TABLE 65 GCC COUNTRIES: OTHER ANTIBODY ENGINEERING & OPTIMIZATION TECHNOLOGIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
- TABLE 66 ANTIGEN DESIGN & PRODUCTION MARKET, BY REGION, 2023–2030 (USD MILLION)
- TABLE 67 NORTH AMERICA: ANTIGEN DESIGN & PRODUCTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
- TABLE 68 EUROPE: ANTIGEN DESIGN & PRODUCTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
- TABLE 69 ASIA PACIFIC: ANTIGEN DESIGN & PRODUCTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
- TABLE 70 LATIN AMERICA: ANTIGEN DESIGN & PRODUCTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
- TABLE 71 MIDDLE EAST: ANTIGEN DESIGN & PRODUCTION MARKET, BY REGION, 2023–2030 (USD MILLION)
- TABLE 72 GCC COUNTRIES: ANTIGEN DESIGN & PRODUCTION MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
- TABLE 73 IMMUNIZATION & HOST MANAGEMENT MARKET, BY REGION, 2023–2030 (USD MILLION)
- TABLE 74 NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
- TABLE 75 EUROPE: IMMUNIZATION & HOST MANAGEMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
- TABLE 76 ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
- TABLE 77 LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
- TABLE 78 MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT MARKET, BY REGION, 2023–2030 (USD MILLION)
- TABLE 79 GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT MARKET, BY COUNTRY, 2023–2030 (USD MILLION)
- TABLE 80 OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY REGION,

2023–2030 (USD MILLION)

TABLE 81 NORTH AMERICA: OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 82 EUROPE: OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 83 ASIA PACIFIC: OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 84 LATIN AMERICA: OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 85 MIDDLE EAST: OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 86 GCC COUNTRIES: OTHER ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 87 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)

TABLE 88 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY REGION, 2023–2030 (USD MILLION)

TABLE 89 NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 90 EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 91 ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 92 LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 93 MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY REGION, 2023–2030 (USD MILLION)

TABLE 94 GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR MOUSE & RAT, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 95 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY REGION, 2023–2030 (USD MILLION)

TABLE 96 NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 97 EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 98 ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 99 LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 100 MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY REGION, 2023–2030 (USD MILLION)

TABLE 101 GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR RABBIT, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 102 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY REGION, 2023–2030 (USD MILLION)

TABLE 103 NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 104 EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 105 ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 106 LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 107 MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY REGION, 2023–2030 (USD MILLION)

TABLE 108 GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CHICKEN, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 109 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY REGION, 2023–2030 (USD MILLION)

TABLE 110 NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 111 EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 112 ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 113 LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 114 MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY REGION, 2023–2030 (USD MILLION)

TABLE 115 GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR CAMELIDS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 116 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR OTHER HOSTS, BY REGION, 2023–2030 (USD MILLION)

TABLE 117 NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR OTHER HOSTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 118 EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET FOR OTHER HOSTS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 119 ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES

MARKET FOR OTHER HOSTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 120 LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES
MARKET FOR OTHER HOSTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 121 MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES
MARKET FOR OTHER HOSTS, BY REGION, 2023–2030 (USD MILLION)
TABLE 122 GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES
MARKET FOR OTHER HOSTS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 123 ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE,
2023–2030 (USD MILLION)
TABLE 124 ANTIBODY DISCOVERY SERVICES MARKET FOR MONOCLONAL
ANTIBODIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 125 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR
MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 126 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET FOR
MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 127 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET FOR
MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 128 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR
MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 129 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET FOR
MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 130 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET
MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 131 ANTIBODY DISCOVERY SERVICES MARKET FOR POLYCLONAL
ANTIBODIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 132 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR
POLYCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 133 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET FOR
POLYCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 134 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET FOR
POLYCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 135 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR
POLYCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 136 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET FOR
POLYCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD MILLION)
TABLE 137 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET FOR
POLYCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 138 ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER
MOLECULES, BY REGION, 2023–2030 (USD MILLION)

TABLE 139 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 140 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 141 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 142 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 143 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY REGION, 2023–2030 (USD MILLION)

TABLE 144 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 145 ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 146 ANTIBODY DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 147 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 148 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 149 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 150 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 151 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 152 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 153 ANTIBODY DISCOVERY SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION)

TABLE 154 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 155 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET FOR

ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 156 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET FOR
ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 157 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR
ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 158 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET FOR
ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 159 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET FOR
ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 160 ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER END
USERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 161 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR
OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 162 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET FOR OTHER
END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 163 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET FOR
OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 164 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET FOR
OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 165 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET FOR
OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)
TABLE 166 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET FOR
OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)
TABLE 167 ANTIBODY DISCOVERY SERVICES MARKET, BY REGION, 2023–2030
(USD MILLION)
TABLE 168 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY
COUNTRY, 2023–2030 (USD MILLION)
TABLE 169 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY
TYPE, 2023–2030 (USD MILLION)
TABLE 170 NORTH AMERICA: ANTIBODY ENGINEERING & OPTIMIZATION
MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)
TABLE 171 NORTH AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES
MARKET, BY HOST, 2023–2030 (USD MILLION)
TABLE 172 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY
MOLECULE, 2023–2030 (USD MILLION)
TABLE 173 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY
END USER, 2023–2030 (USD MILLION)
TABLE 174 NORTH AMERICA: KEY MACROINDICATORS
TABLE 175 US: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030

(USD MILLION)

TABLE 176 US: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 177 US: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)

TABLE 178 US: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 179 US: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 180 CANADA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 181 CANADA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 182 CANADA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)

TABLE 183 CANADA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 184 CANADA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 185 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 186 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 187 EUROPE: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 188 EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)

TABLE 189 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 190 EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 191 EUROPE: KEY MACROINDICATORS

TABLE 192 GERMANY: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 193 GERMANY: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 194 GERMANY: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)

TABLE 195 GERMANY: ANTIBODY DISCOVERY SERVICES MARKET, BY

MOLECULE, 2023–2030 (USD MILLION)

TABLE 196 GERMANY: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 197 UK: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 198 UK: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 199 UK: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)

TABLE 200 UK: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 201 UK: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 202 FRANCE: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 203 FRANCE: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 204 FRANCE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)

TABLE 205 FRANCE: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 206 FRANCE: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 207 ITALY: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 208 ITALY: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 209 ITALY: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)

TABLE 210 ITALY: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 211 ITALY: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 212 SPAIN: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 213 SPAIN: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 214 SPAIN: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)

TABLE 215 SPAIN: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 216 SPAIN: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 217 REST OF EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 218 REST OF EUROPE: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 219 REST OF EUROPE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)

TABLE 220 REST OF EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 221 REST OF EUROPE: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 222 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 223 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 224 ASIA PACIFIC: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 225 ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)

TABLE 226 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 227 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 228 ASIA PACIFIC: KEY MACROINDICATORS

TABLE 229 CHINA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 230 CHINA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 231 CHINA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)

TABLE 232 CHINA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 233 CHINA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 234 JAPAN: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 235 JAPAN: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 236 JAPAN: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)

TABLE 237 JAPAN: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 238 JAPAN: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 239 INDIA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 240 INDIA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 241 INDIA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)

TABLE 242 INDIA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 243 INDIA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 244 SOUTH KOREA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 245 SOUTH KOREA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 246 SOUTH KOREA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)

TABLE 247 SOUTH KOREA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 248 SOUTH KOREA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 249 AUSTRALIA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 250 AUSTRALIA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 251 AUSTRALIA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)

TABLE 252 AUSTRALIA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 253 AUSTRALIA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 254 REST OF ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET,

BY TYPE, 2023–2030 (USD MILLION)

TABLE 255 REST OF ASIA PACIFIC: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 256 REST OF ASIA PACIFIC: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)

TABLE 257 REST OF ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 258 REST OF ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 259 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 260 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 261 LATIN AMERICA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 262 LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)

TABLE 263 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 264 LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 265 LATIN AMERICA: KEY MACROINDICATORS

TABLE 266 BRAZIL: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 267 BRAZIL: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 268 BRAZIL: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)

TABLE 269 BRAZIL: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 270 BRAZIL: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 271 MEXICO: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 272 MEXICO: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 273 MEXICO: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)

TABLE 274 MEXICO: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE,

2023–2030 (USD MILLION)

TABLE 275 MEXICO: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 276 REST OF LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 277 REST OF LATIN AMERICA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 278 REST OF LATIN AMERICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)

TABLE 279 REST OF LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 280 REST OF LATIN AMERICA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 281 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 282 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 283 MIDDLE EAST: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 284 MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)

TABLE 285 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 286 MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 287 MIDDLE EAST: KEY MACROINDICATORS

TABLE 288 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 289 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 290 GCC COUNTRIES: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 291 GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)

TABLE 292 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 293 GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 294 UAE: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE,

2023–2030 (USD MILLION)

TABLE 295 UAE: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 296 UAE: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)

TABLE 297 UAE: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 298 UAE: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 299 KINGDOM OF SAUDI ARABIA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 300 KINGDOM OF SAUDI ARABIA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 301 KINGDOM OF SAUDI ARABIA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)

TABLE 302 KINGDOM OF SAUDI ARABIA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 303 KINGDOM OF SAUDI ARABIA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 304 REST OF GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 305 REST OF GCC COUNTRIES: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 306 REST OF GCC COUNTRIES: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)

TABLE 307 REST OF GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 308 REST OF GCC COUNTRIES: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 309 REST OF MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 310 REST OF MIDDLE EAST: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 311 REST OF MIDDLE EAST: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)

TABLE 312 REST OF MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 313 REST OF MIDDLE EAST: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 314 AFRICA: ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)

TABLE 315 AFRICA: ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION)

TABLE 316 AFRICA: IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2023–2030 (USD MILLION)

TABLE 317 AFRICA: ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 318 AFRICA: ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 319 AFRICA: KEY MACROINDICATORS

TABLE 320 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN ANTIBODY DISCOVERY SERVICES MARKET, JANUARY 2022–AUGUST 2025

TABLE 321 ANTIBODY DISCOVERY SERVICES MARKET: DEGREE OF COMPETITION

TABLE 322 ANTIBODY DISCOVERY SERVICES MARKET: REGION FOOTPRINT

TABLE 323 ANTIBODY DISCOVERY SERVICES MARKET: TYPE FOOTPRINT

TABLE 324 ANTIBODY DISCOVERY SERVICES MARKET: HOST FOOTPRINT

TABLE 325 ANTIBODY DISCOVERY SERVICES MARKET: MOLECULE FOOTPRINT

TABLE 326 ANTIBODY DISCOVERY SERVICES MARKET: LIST OF KEY STARTUPS/SME PLAYERS

TABLE 327 ANTIBODY DISCOVERY SERVICES MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY TYPE AND REGION

TABLE 328 ANTIBODY DISCOVERY SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2022–AUGUST 2025

TABLE 329 ANTIBODY DISCOVERY SERVICES MARKET: DEALS, JANUARY 2022–AUGUST 2025

List Of Figures

LIST OF FIGURES

FIGURE 1 ANTIBODY DISCOVERY SERVICES MARKET SEGMENTATION & REGIONAL SCOPE

FIGURE 2 ANTIBODY DISCOVERY SERVICES MARKET: YEARS CONSIDERED

FIGURE 3 ANTIBODY DISCOVERY SERVICES MARKET: RESEARCH DESIGN

FIGURE 4 ANTIBODY DISCOVERY SERVICES MARKET: BREAKDOWN OF PRIMARIES (SUPPLY- AND DEMAND-SIDE PARTICIPANTS)

FIGURE 5 ANTIBODY DISCOVERY SERVICES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024

FIGURE 6 COMPANY REVENUE ANALYSIS-BASED MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH

FIGURE 7 REVENUE SHARE ANALYSIS: ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC (US), 2024

FIGURE 8 ANTIBODY DISCOVERY SERVICES MARKET SIZE VALIDATION FROM PRIMARY EXPERTS

FIGURE 9 ANTIBODY DISCOVERY SERVICES MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH

FIGURE 10 ANTIBODY DISCOVERY SERVICES MARKET: CAGR PROJECTIONS

FIGURE 11 ANTIBODY DISCOVERY SERVICES MARKET: DATA TRIANGULATION METHODOLOGY

FIGURE 12 ANTIBODY DISCOVERY SERVICES MARKET, BY TYPE, 2025 VS. 2030 (USD MILLION)

FIGURE 13 ANTIBODY ENGINEERING & OPTIMIZATION MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)

FIGURE 14 IMMUNIZATION & HOST MANAGEMENT SERVICES MARKET, BY HOST, 2025 VS. 2030 (USD MILLION)

FIGURE 15 ANTIBODY DISCOVERY SERVICES MARKET, BY MOLECULE, 2025 VS. 2030 (USD MILLION)

FIGURE 16 ANTIBODY DISCOVERY SERVICES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)

FIGURE 17 ANTIBODY DISCOVERY SERVICES MARKET: REGIONAL SNAPSHOT

FIGURE 18 SNAPSHOT: GLOBAL ANTIBODY DISCOVERY SERVICES MARKET SIZE, GROWTH RATE, AND FORECAST (USD MILLION)

FIGURE 19 INCREASING VENTURE FUNDING AND INVESTMENTS TO DRIVE MARKET

FIGURE 20 US AND MONOCLONAL ANTIBODIES COMMANDED LARGEST NORTH AMERICAN MARKET SHARE IN 2024

FIGURE 21 MONOCLONAL ANTIBODIES TO ACCOUNT FOR LARGEST MARKET SHARE THROUGHOUT FORECAST PERIOD

FIGURE 22 CHINA TO REGISTER HIGHEST CAGR FROM 2025 TO 2030

FIGURE 23 ANTIBODY ENGINEERING & OPTIMIZATION SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2024

FIGURE 24 ANTIBODY DISCOVERY SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

FIGURE 25 ANTIBODY DISCOVERY SERVICES MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS

FIGURE 26 ANTIBODY DISCOVERY SERVICES MARKET: VALUE CHAIN ANALYSIS

FIGURE 27 ANTIBODY DISCOVERY SERVICES MARKET: ECOSYSTEM ANALYSIS

FIGURE 28 NIH FUNDING FOR ANTIBODY DISCOVERY, 2014–2025 (USD MILLION)

FIGURE 29 TOP PATENT APPLICANTS/OWNERS AND NUMBER OF PATENTS GRANTED IN ANTIBODY DISCOVERY SERVICES MARKET, JANUARY

2014–DECEMBER 2024

FIGURE 30 ANTIBODY DISCOVERY SERVICES MARKET: PORTER'S FIVE FORCES ANALYSIS

FIGURE 31 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY TYPE

FIGURE 32 KEY BUYING CRITERIA FOR MAJOR END USERS

FIGURE 33 IMPACT OF AI/GEN AI ON ANTIBODY DISCOVERY SERVICES MARKET

FIGURE 34 NORTH AMERICA: ANTIBODY DISCOVERY SERVICES MARKET SNAPSHOT

FIGURE 35 ASIA PACIFIC: ANTIBODY DISCOVERY SERVICES MARKET SNAPSHOT

FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS IN ANTIBODY DISCOVERY SERVICES MARKET, 2020–2024 (USD MILLION)

FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS IN ANTIBODY DISCOVERY SERVICES MARKET (2024)

FIGURE 38 ANTIBODY DISCOVERY SERVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024

FIGURE 39 ANTIBODY DISCOVERY SERVICES MARKET: COMPANY FOOTPRINT

FIGURE 40 ANTIBODY DISCOVERY SERVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024

FIGURE 41 EV/EBITDA OF KEY PLAYERS

FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY PLAYERS

FIGURE 43 ANTIBODY DISCOVERY SERVICES MARKET: BRAND/SERVICE COMPARATIVE ANALYSIS

FIGURE 44 WUXI BIOLOGICS: COMPANY SNAPSHOT
FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
FIGURE 46 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
FIGURE 47 EVOTEC: COMPANY SNAPSHOT
FIGURE 48 BIOCYTOGEN: COMPANY SNAPSHOT
FIGURE 49 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT
FIGURE 50 AURIGENE PHARMACEUTICAL SERVICES LTD. (DR. REDDY'S LABORATORIES): COMPANY SNAPSHOT
FIGURE 51 SINO BIOLOGICAL, INC.: COMPANY SNAPSHOT
FIGURE 52 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT
FIGURE 53 GENSCRIPT: COMPANY SNAPSHOT
FIGURE 54 TWIST BIOSCIENCE: COMPANY SNAPSHOT
FIGURE 55 HARBOUR BIOMED: COMPANY SNAPSHOT
FIGURE 56 ARAGEN LIFE SCIENCES LTD.: COMPANY SNAPSHOT
FIGURE 57 DANAHER CORPORATION: COMPANY SNAPSHOT
FIGURE 58 VIVA BIOTECH: COMPANY SNAPSHOT
FIGURE 59 IMMUNOPRECISE ANTIBODIES LTD.: COMPANY SNAPSHOT
FIGURE 60 FUSION ANTIBODIES: COMPANY SNAPSHOT

I would like to order

Product name: Antibody Discovery Services Market by Type (Target Identification, Antibody Engineering (Technology (Hybridoma, Phage Display, Single Cell)), Immunization), Host (Mouse, Rat, Rabbit, Chicken, Camelids), Molecule (Monoclonal) - Global Forecast to 2030

Product link: <https://marketpublishers.com/r/A4CA08D15880EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A4CA08D15880EN.html>